Complementary Presence of HBV Humoral and T-cell Response Provides Protective Immunity after Neonatal Immunization

作者全名："Huang, Yunmei; Yang, Yuting; Wu, Tingting; Li, Zhiyu; Xu, Hongmei; Huang, Ailong; Zhao, Yao"

作者地址："[Huang, Yunmei; Yang, Yuting; Wu, Tingting; Li, Zhiyu; Zhao, Yao] Chongqing Med Univ, China Int Sci & Technol Cooperat Base Child Dev &, Natl Clin Res Ctr Child Hlth & Disorders,Children, Minist Educ,Key Lab Child Dev & Disorders,Chongqi, Chongqing, Peoples R China; [Xu, Hongmei] Chongqing Med Univ, Dept Infect, Childrens Hosp, Chongqing, Peoples R China; [Huang, Ailong] Chongqing Med Univ, Inst Viral Hepatitis, Key Lab Mol Biol Infect Dis, Minist Educ, Chongqing, Peoples R China"

通信作者："Zhao, Y (通讯作者)，Chongqing Med Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth & Disorders, Chongqing 400014, Peoples R China."

来源：JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY

ESI学科分类：　

WOS号：WOS:000852749900012

JCR分区：Q2

影响因子：3.6

年份：2022

卷号：10

期号：4

开始页：660

结束页：668

文献类型：Article

关键词：Hepatitis B virus; Hepatitis B vaccine; Booster; Children

摘要："Background and Aims: Hepatitis B vaccination is the most cost effective way to prevent hepatitis B virus (HBV) infection. Hepatitis B vaccine (HepB) efficacy is usually assessed by anti-hepatitis B surface antigen (HBsAg) level, but there are few reports of humoral and cellular immune responses to HepB in children after neonatal vaccination. Methods: A group of 100 children with a history of primary hepatitis B immunization were included in this study to evaluate the efficacy of HepB. Blood samples were obtained from 80 children before, and 41 children after, a single HepB booster dose. Children with low anti-HBsAg (HBs) titers of < 100 mIU/mL received a booster dose after giving their informed consent. Anti-HBsAg, T-cell response and percentage of B-cell subsets were assayed before and after the booster. Results: Of the 80 children, 81.36% had positive T cell and anti-HBsAg responses at baseline. After the booster dose, the anti-HBsAg titer (p < 0.0001), positive HBsAg-specific T-cell response (p=0.0036), and spot-forming cells (p=0.0003) increased significantly. Compared with pre-existing anti-HBsAg titer < 10 mIU/mL, the anti-HBsAg (p=0.0005) and HBsAg-specific T-cell responses (p < 0.0001) increased significantly in preexisting anti-HBsAg titer between 10 and 100 mIU/mL group. Change of the HBV-specific humoral response was the reverse of the T-cell response with age. Peripheral blood lymphocytes, B cells, and subset frequency decreased. Conclusions: HBV immunization protection persisted at least 13 years after primary immunization because of the complementary presence of HBV-specific humoral antibodies and a T-cell immune response. One dose of a HepB booster induced protective anti-HBsAg and promoted an HBsAg-specific T-cell response. In HBV endemic regions, a HepB booster is recommended to children without anti-HBsAg because of effectiveness in HBV prevention."

基金机构：National Clinical Research Center for Child Health and Disorders General project [NCRCCHD-2019-GP-04]; Central Government Guides Local Science and Technology Development projects-demonstration of Science and Technology Innovation projects; National Natural Science Foundation of China [81371876]; Outstanding Youth Foundation of Children's Hospital of Chongqing Medical University

基金资助正文："This study was supported by the National Clinical Research Center for Child Health and Disorders General project (No. NCRCCHD-2019-GP-04), Central Government Guides Local Science and Technology Development projects-demonstration of Science and Technology Innovation projects, National Natural Science Foundation of China (No. 81371876), Outstanding Youth Foundation of Children's Hospital of Chongqing Medical University."